JPH09500027A - 液体の安定なチオール活性化剤 - Google Patents
液体の安定なチオール活性化剤Info
- Publication number
- JPH09500027A JPH09500027A JP7529150A JP52915095A JPH09500027A JP H09500027 A JPH09500027 A JP H09500027A JP 7529150 A JP7529150 A JP 7529150A JP 52915095 A JP52915095 A JP 52915095A JP H09500027 A JPH09500027 A JP H09500027A
- Authority
- JP
- Japan
- Prior art keywords
- thiol
- solution
- liquid
- activator
- thiol activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012190 activator Substances 0.000 title claims abstract description 79
- 239000007788 liquid Substances 0.000 title claims description 58
- 125000003396 thiol group Chemical class [H]S* 0.000 title description 2
- 150000003573 thiols Chemical class 0.000 claims abstract description 118
- 102000004420 Creatine Kinase Human genes 0.000 claims abstract description 89
- 108010042126 Creatine kinase Proteins 0.000 claims abstract description 89
- 239000000243 solution Substances 0.000 claims abstract description 84
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 64
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 36
- 229930195725 Mannitol Natural products 0.000 claims abstract description 35
- 239000000594 mannitol Substances 0.000 claims abstract description 35
- 235000010355 mannitol Nutrition 0.000 claims abstract description 35
- 239000003381 stabilizer Substances 0.000 claims abstract description 29
- 239000007864 aqueous solution Substances 0.000 claims abstract description 22
- 238000003860 storage Methods 0.000 claims abstract description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 45
- 239000000872 buffer Substances 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 27
- 239000002738 chelating agent Substances 0.000 claims description 26
- 239000007853 buffer solution Substances 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 23
- 229910021645 metal ion Inorganic materials 0.000 claims description 21
- 238000003556 assay Methods 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- 238000000021 kinase assay Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 8
- 229940123457 Free radical scavenger Drugs 0.000 claims description 7
- -1 dithiotre Ititol Chemical compound 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 239000002516 radical scavenger Substances 0.000 claims description 7
- 230000000087 stabilizing effect Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 108010024636 Glutathione Proteins 0.000 claims description 6
- 239000012062 aqueous buffer Substances 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 229940096405 magnesium cation Drugs 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
- PVQKQWMEXZGTMR-UHFFFAOYSA-N 1,5-dimethylpyrazolo[3,4-d]pyrimidin-4-one Chemical group N1=CN(C)C(=O)C2=C1N(C)N=C2 PVQKQWMEXZGTMR-UHFFFAOYSA-N 0.000 claims description 2
- GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 claims description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- VLCDUOXHFNUCKK-UHFFFAOYSA-N N,N'-Dimethylthiourea Chemical compound CNC(=S)NC VLCDUOXHFNUCKK-UHFFFAOYSA-N 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 230000006866 deterioration Effects 0.000 claims description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 102000016938 Catalase Human genes 0.000 claims 1
- 108010053835 Catalase Proteins 0.000 claims 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims 1
- 229960000958 deferoxamine Drugs 0.000 claims 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 235000019149 tocopherols Nutrition 0.000 claims 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 description 47
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000006046 creatine Substances 0.000 description 5
- 229960003624 creatine Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000009920 chelation Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000511343 Chondrostoma nasus Species 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000006701 autoxidation reaction Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000011095 buffer preparation Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000003674 kinase activity assay Methods 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- GWJVAUUOXXKJIA-MLWJPKLSSA-N (2S)-6-amino-2-(2-sulfanylpropanoylamino)hexanoic acid Chemical compound CC(S)C(=O)N[C@H](C(O)=O)CCCCN GWJVAUUOXXKJIA-MLWJPKLSSA-N 0.000 description 1
- OQPDPIPLWCUACY-UHFFFAOYSA-N 2-aminoethylthiourea;hydrobromide Chemical compound [Br-].NCC[NH+]=C(N)S OQPDPIPLWCUACY-UHFFFAOYSA-N 0.000 description 1
- GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000975394 Evechinus chloroticus Species 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 1
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007811 spectroscopic assay Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/50—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving creatine phosphokinase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)生物学的分子を活性化するためのチオール活性化剤; (b)チオール活性化剤を安定化するための安定化剤;及び (c)チオール活性化剤と安定化剤とを溶解できる液体であって、溶解した チオール活性化剤がその液体中で安定化剤によって安定化する液体 を含んでなる組成物。 2.チオール活性化剤が、グルタチオン、臭化 2−アミノエチルイソチオウ ロニウム、チオグリコール酸、システイン、メルカプトエタノール、ジチオトレ イトール、モノチオグリセロール、グルタチオン、ジチオエリトレイトール及び N−アセチル−L−システインからなる群から選択される請求の範囲第1項記載 の組成物。 3.チオール活性化剤がN−アセチル−L−システインである請求の範囲第2 項記載の組成物。 4.安定化剤が遊離ラジカルスカベンジャーである請求の範囲第1項記載の組 成物。 5.遊離ラジカルスカベンジャーがイノシトール、トコフェロール、マンニト ール、スーパーオキシドジムターゼ、カタラーゼ、グルタチオンペルオキシダー ゼ、N−2−メルカプトプロピオニルグリシン、ジメチルチオ尿素、グルタチオ ン、21−アミノステロイド類、デフェロキサミン、アロプリノール、ジメチル スルフォキシド及びコエンチームQからなる群から選択される請求の範囲第4項 記載の組成物。 6.液体が、その液体を生理的pHに維持することができる緩衝 水溶液を含んでなる請求の範囲第1項記載の組成物。 7.液体から所望でない金属イオンを除去するためのキレート剤をさらに含む 請求の範囲第1項記載の組成物。 8.キレート剤が液体中に約0.025mmol/Lから約4mmol/Lの 濃度で存在する請求の範囲第7項記載の組成物。 9.キレート剤がEGTA、BHN及びEDTAからなる群から選択される請 求の範囲第7項記載の組成物。 10.チオール活性化剤が保存条件下で、少なくとも約1年間は実質的に減少し ないチオール活性化能力を保有する請求の範囲第1項記載の組成物。 11.チオール活性化剤が保存条件下で、少なくとも約2年間は実質的に減少し ないチオール活性化能力を保有する請求の範囲第1項記載の組成物。 12.チオール活性化剤が開放ビン条件で、少なくとも約28日間は実質的に減 少しないチオール活性化能力を保有する請求の範囲第1項記載の組成物。 13.チオール活性化剤が開放ビン条件下で、少なくとも約60日間は実質的に 減少しないチオール活性化能力を保有する請求の範囲第1項記載の組成物。 14.生物学的分子の活性化を促進することができる金属イオンをさらに含む請 求の範囲第1項記載の組成物。 15.金属イオンがマグネシウムカチオンである請求の範囲第14項記載の組成 物。 16.安定化剤が液体中に約組成物5mmol/Lから約550mmol/Lの 濃度で存在する請求の範囲第1項記載の組成物。 17.(a)生物学的分子を活性化するためのチオール活性化剤、 (b)チオール活性化剤を安定化するための遊離ラジカルスカベンジャー 、 (c)生物学的分子の活性を促進するための金属イオン、 (d)キレート剤、及び (e)チオール活性化剤、安定化剤、金属イオン及びキレート剤を緩衝液 に溶解させて、溶液中に存在するチオールの顕著な品質低下を保存条件下で少な くとも約1年間、開放ビン条件下で少なくとも約28日間阻止して安定に保つ液 体安定チオール活性化剤溶液を形成することができる水性緩衝液 を含んでなる液体の安定なチオール活性化剤溶液。 18.(a)水性緩衝液; (b)N−アセチル−L−システイン; (c)エチレンジアミン四酢酸; (d)マンニトール;及び (e)マグネシウム を含んでなり、ここでエチレンジアミン四酢酸とマンニトールの濃度が水性緩衝 液中のN−アセチル−L−システインを安定化するように選択される クレアチンキナーゼ検定のための試薬。 19.(a)チオール活性化剤と安定化剤とを溶解するための液体を選択し; (b)チオール活性化剤を前記液体に添加し;そして (c)前記液体に溶解したチオール活性化剤を安定化することができる安 定化剤を前記液体に添加し; それによって液体の安定なチオール活性化剤溶液を作る 各工程を含んでなり、ここで、前記溶液中でチオール活性化剤は安定であり、そ のチオール活性化能力は保存条件下で少なくとも約1年間、開放ビン条件下で少 なくとも約28日間は実質的に減少せずに保有される 液体の安定なチオール活性化剤溶液の製造方法。 20.(a)水性緩衝液を選択し; (b)EDTAを前記緩衝液に添加し;そして (c)マンニトールを前記緩衝液に添加する 各工程を含んでなり、ここで前記緩衝液はEDTAとマンニトールとを溶解する ことができて、この方法により安定なNACの水溶液が得られる 安定なNACの水溶液の製造方法。 21.(a)液体の安定なチオール活性化剤溶液を調製し; (b)生理的流体の試験サンプルを液体の安定なチオール活性化剤に加え ;そして (c)試験サンプル中のクレアチンキナーゼ活性を検出する各工程を含ん でなるクレアチンキナーゼ活性の検定法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23926094A | 1994-05-06 | 1994-05-06 | |
| US08/239,260 | 1994-05-06 | ||
| PCT/US1995/005702 WO1995030769A1 (en) | 1994-05-06 | 1995-05-05 | Liquid stable thiol activator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09500027A true JPH09500027A (ja) | 1997-01-07 |
| JP3619865B2 JP3619865B2 (ja) | 2005-02-16 |
Family
ID=22901361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52915095A Expired - Fee Related JP3619865B2 (ja) | 1994-05-06 | 1995-05-05 | 液体の安定なチオール活性化剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5700653A (ja) |
| EP (1) | EP0707658B1 (ja) |
| JP (1) | JP3619865B2 (ja) |
| AT (1) | ATE221919T1 (ja) |
| AU (1) | AU692547B2 (ja) |
| CA (1) | CA2165808A1 (ja) |
| DE (1) | DE69527686T2 (ja) |
| ES (1) | ES2180632T3 (ja) |
| WO (1) | WO1995030769A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010263839A (ja) * | 2009-05-15 | 2010-11-25 | Asahi Kasei Pharma Kk | Impdh含有組成物及びimpdhの安定化方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19755079A1 (de) | 1997-12-11 | 1999-06-17 | Roche Diagnostics Gmbh | Stabilisiertes Reagenz und Verfahren zur Bestimmung von Creatin-Kinase |
| US5908864A (en) * | 1998-05-28 | 1999-06-01 | Dymatize Enterprises | Creatine gel |
| ES2272037T3 (es) | 1998-12-22 | 2007-04-16 | Olympus Life And Material Science Europa Gmbh | Reactivo liquido para la deteccion de creatina cinasa. |
| WO2000040746A1 (en) * | 1999-01-08 | 2000-07-13 | Medical Analysis Systems, Inc. | Compositions and methods for stabilizing thiol-containing biomolecules |
| US20060020035A1 (en) * | 2004-03-11 | 2006-01-26 | Oregon Health & Science University | Bone marrow protection with N-acetyl-L-cysteine |
| US8148356B2 (en) | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| AU2011202871B2 (en) * | 2005-08-24 | 2014-06-12 | Cumberland Pharmaceuticals Inc. | Acetylcysteine composition and uses therefor |
| SG10202010355PA (en) * | 2010-03-12 | 2020-11-27 | Berg Llc | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| EP2720680B1 (en) | 2011-06-17 | 2020-02-12 | Berg LLC | Inhalable pharmaceutical compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2648759C3 (de) * | 1976-10-27 | 1979-05-31 | Boehringer Mannheim Gmbh, 6800 Mannheim | Stabilisierungsmittel für Enzyme |
| US4339533A (en) * | 1980-07-30 | 1982-07-13 | Technicon Instruments Corporation | Stabilization of creatine kinase (CK) and its application as a reference standard |
| US4883762A (en) * | 1983-06-06 | 1989-11-28 | Ciba Corning Diagnostics Corp. | Stabilized isoenzyme control products |
| JPS6188899A (ja) * | 1984-10-05 | 1986-05-07 | Unitika Ltd | クレアチンキナ−ゼ定量用試薬 |
| JPS62104598A (ja) * | 1985-11-01 | 1987-05-15 | Yatoron:Kk | クレアチンキナ−ゼ測定用試薬 |
| FR2610626B1 (fr) * | 1987-02-09 | 1989-05-19 | Oreal | Nouveau systeme anti-oxydant a base d'un ester d'ascorbyle stabilise, contenant en association au moins un agent complexant et au moins un thiol, et compositions contenant un tel systeme anti-oxydant |
| JPS63283600A (ja) * | 1987-05-18 | 1988-11-21 | Fuji Photo Film Co Ltd | クレアチンキナ−ゼ活性測定用分析要素 |
| JPH0690202B2 (ja) * | 1988-04-06 | 1994-11-14 | ユニチカ株式会社 | クレアチンキナーゼ活性測定用試薬およびそれを用いる測定方法 |
| CA2028593C (en) * | 1989-10-31 | 2007-08-21 | Douglas R. Brandt | Stabilized enzyme compositions |
| IT1242642B (it) * | 1990-04-17 | 1994-05-16 | Alfa Wassermann Spa | Formulazioni iniettabili contenenti naproxen sale sodico. |
| US5192657A (en) * | 1990-12-18 | 1993-03-09 | Ortho Diagnostic Systems, Inc. | Stabilized proteolytic solution and reagent kit |
| JPH05111396A (ja) * | 1991-07-17 | 1993-05-07 | Oriental Yeast Co Ltd | クレアチンキナ−ゼの活性測定方法 およびそれに用いる試薬 |
| US5298406A (en) * | 1992-09-14 | 1994-03-29 | E. I. Du Pont De Nemours And Company | Formulation for stabilizing enzymatic activity and immunoreactivity of creatine kinase and creatine kinase isoenzymes |
-
1995
- 1995-05-05 ES ES95918415T patent/ES2180632T3/es not_active Expired - Lifetime
- 1995-05-05 CA CA002165808A patent/CA2165808A1/en not_active Abandoned
- 1995-05-05 DE DE69527686T patent/DE69527686T2/de not_active Expired - Fee Related
- 1995-05-05 AT AT95918415T patent/ATE221919T1/de not_active IP Right Cessation
- 1995-05-05 WO PCT/US1995/005702 patent/WO1995030769A1/en not_active Ceased
- 1995-05-05 AU AU24367/95A patent/AU692547B2/en not_active Ceased
- 1995-05-05 JP JP52915095A patent/JP3619865B2/ja not_active Expired - Fee Related
- 1995-05-05 EP EP95918415A patent/EP0707658B1/en not_active Expired - Lifetime
- 1995-10-09 US US08/541,473 patent/US5700653A/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010263839A (ja) * | 2009-05-15 | 2010-11-25 | Asahi Kasei Pharma Kk | Impdh含有組成物及びimpdhの安定化方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE221919T1 (de) | 2002-08-15 |
| WO1995030769A1 (en) | 1995-11-16 |
| JP3619865B2 (ja) | 2005-02-16 |
| US5700653A (en) | 1997-12-23 |
| EP0707658B1 (en) | 2002-08-07 |
| DE69527686T2 (de) | 2003-04-03 |
| CA2165808A1 (en) | 1995-11-16 |
| ES2180632T3 (es) | 2003-02-16 |
| DE69527686D1 (de) | 2002-09-12 |
| AU692547B2 (en) | 1998-06-11 |
| EP0707658A1 (en) | 1996-04-24 |
| AU2436795A (en) | 1995-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klingenberg | Nicotinamide-adenine dinucleotides (NAD, NADP, NADH, NADPH): spectrophotometric and fluorimetric methods | |
| EP0034213B1 (en) | A stabilized aqueous coenzyme solution for use in a clinical assay, a method of stabilizing a labile coenzyme in an aqueous clinical assay solution and a kit for use in said clinical assay | |
| JP2539225B2 (ja) | グルコ−ス定量用安定化液体酵素組成物、それを用いる試薬キット及び定量方法 | |
| JPH09500027A (ja) | 液体の安定なチオール活性化剤 | |
| WO1996015256A1 (en) | Enzymatic composition for clinical examination | |
| JPH01108997A (ja) | 血液又は血液から導出した試料中の血清のフルクトスアミン含量を特異的に測定する方法及び試薬、及び非特異的還元作用を有するか、又は/及び溷濁を惹起する試料成分を除去する方法 | |
| JPH06277097A (ja) | 血清中の二酸化炭素の測定のための安定な単一液体試薬 | |
| JP2711721B2 (ja) | グルコースを含有する試料中の1,5―アンヒドログルシトールの定量法 | |
| US4888289A (en) | Reagent for determining creatine kinase | |
| US5716797A (en) | Stable two-part reagent for the measurement of creatine kinase activity | |
| EP0685561B1 (en) | Reagent for assaying creatine kinase | |
| JP5843072B2 (ja) | 特定物質の測定方法および特定物質測定用キット | |
| JP4182859B2 (ja) | クレアチンキナーゼ測定用液状試薬キットおよびその安定化方法 | |
| JP4651237B2 (ja) | 還元型ニコチンアミドアデニンジヌクレオチド類の安定化方法及び試薬 | |
| JPH0919296A (ja) | 発色基質の安定化方法、試薬及び微量成分の定量法 | |
| JP5633669B2 (ja) | Adpの測定方法およびadp測定用キット | |
| Wilkinson | LDH1 (“2-Hydroxybutyrate Dehydrogenase”): UV-Assay | |
| JPH10225300A (ja) | グルコースまたはadpの高感度測定法 | |
| JP4820289B2 (ja) | カルボニックアンヒドラーゼi活性の測定法 | |
| WO2000040746A1 (en) | Compositions and methods for stabilizing thiol-containing biomolecules | |
| JPS59198999A (ja) | クレアチンキナ−ゼ測定用組成物 | |
| JP5982608B2 (ja) | クレアチンキナーゼ活性の測定試薬 | |
| JPH07108239B2 (ja) | ピルビン酸の定量方法及び該方法を利用する生体成分の定量方法 | |
| JPH08242893A (ja) | クレアチンキナーゼ活性測定用液状試薬 | |
| JP2006075111A (ja) | ビタミンb6酵素を用いた試薬の安定化法およびその試薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040309 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040825 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041012 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041020 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041020 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081126 Year of fee payment: 4 |
|
| LAPS | Cancellation because of no payment of annual fees |